[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexuality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexuality":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,73,104,133,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100632735","sexual-health-education-during-pregnancy-100632735",false,"NCT07517549","Sexual Health Education During Pregnancy","The Effect Of Sexual Counseling Based On the Extended Plissit Model On Sexual Function, Marital Adjustment, Sexual Quality Of Life, Depression, Anxiety, And Stress During Pregnancy And Postpartum","Eligibility criteria;\n\n* Volunteers to participate in the research,\n* primary school graduate,\n* Pregnant between 16-20 weeks\n* Having a single pregnancy,\n* Able to understand and speak Turkish,\n* Living with his wife for the past four weeks,\n* No threat of abortion or premature birth,\n\nExclusion Criteria:\n\n* Someone who has been diagnosed with a chronic illness,\n* People with diagnosed physical and mental health issues,\n* Someone who has been diagnosed with a psychological disorder,\n* Having a high-risk pregnancy,\n* Having an IVF pregnancy,\n* Low threat,\n* Anyone who has been diagnosed with any sexually transmitted disease, either themselves or in their partner,\n* Those using medications that may negatively affect sexual function,\n* including antipsychotics, antihypertensives, phenobarbital, and opioids.",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","This experimental, randomized controlled, single-blind study includes intervention and control groups. Pregnant women between 16 and 20 weeks of gestation who meet the inclusion criteria and agree to participate will be included in the study. Pregnant women will be randomly assigned to groups. Pre-test data will be collected from both groups. The intervention group will receive sexual counseling training in two sessions, face-to-face and in groups, until week 22. Second test data will be collected after week 37 (before delivery), and final test data will be collected three months after delivery. This study is expected to have a significant impact on women's lives, as this topic is considered taboo in our country, leading to a lack of open discussion and the prevalence of misconceptions and false beliefs (sexual myths).",[28,29,30],"Sexuality","Depression","Pregnancy Related",[28,32,33],"Pregnancy","Anxiety","RECRUITING","2026-04-01",{"date":37,"type":38},"2026-04-08","ACTUAL",{"date":40,"type":38},"2026-03-15",{"date":42,"type":22},"2026-11-30",{"name":44,"class":45},"Ordu University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100621883","spousal-support-and-sexual-quality-of-life-in-postmenopausal-women-100621883","NCT07376408","Spousal Support and Sexual Quality of Life in Postmenopausal Women","The Effect of Spousal Support on Sexual Quality of Life in Postmenopausal Women","Inclusion Criteria:\n\n* Postmenopausal status, defined as at least 12 consecutive months of amenorrhea\n* Having a partner\n* Voluntary agreement to participate in the study and provision of written informed consent\n\nExclusion Criteria:\n\n* Visual, cognitive, or other impairments that prevent completion of the study questionnaires\n* History of major gynecological surgery within the past 6 months",{"count":55,"type":22},84,"OBSERVATIONAL","Menopause is a natural transition period in women's lives characterized by concurrent hormonal, psychological, and relational changes. During the postmenopausal period, hormonal alterations are not limited to physical symptoms but also have significant effects on psychological well-being, interpersonal relationships, and particularly sexual quality of life. Common concerns during this period include decreased sexual desire, vaginal dryness, pelvic discomfort, and reduced sexual satisfaction, all of which may negatively affect overall quality of life. Sexual quality of life is influenced not only by biological factors but also by psychological and relational dimensions.\n\nThe quality of partner relationships and perceived partner support play an important role in women's adaptation to sexual changes during the postmenopausal period. However, partner support during menopause is often reported to be insufficient, which may adversely affect sexual well-being. Despite this, evidence examining the relationship between perceived partner support and sexual quality of life in postmenopausal women remains limited.\n\nThe aim of this study is to examine the effect of perceived partner support on sexual quality of life in postmenopausal women. Through this investigation, the explanatory role of partner support in postmenopausal sexual well-being is aimed.",[59,60,28],"Postmenopausal","Support",[59,28,62,60],"Quality of Life","NOT_YET_RECRUITING","2026-01-30",{"date":66,"type":38},"2026-02-03",{"date":68,"type":22},"2026-02",{"date":70,"type":22},"2027-02",{"name":72,"class":45},"Istanbul University - Cerrahpasa",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100497748","assessment-of-womens-sexual-quality-of-life-after-benign-adnexal-surgery-using-vnotes-approach-100497748","NCT05761275","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach in Comparison to Conventional Laparoscopy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged from 18 to 70 years\n* Discernment capacity with oral and written consent signed\n* Heterosexual intercourse (with vaginal penetration) within four weeks prior to inclusion in the study\n\nExclusion Criteria:\n\n* History of rectal surgery.\n* Suspected rectovaginal\u002Fretrocervical endometriosis.\n* History of brachytherapy or pelvic radiation.\n* Suspected malignancy.\n* History of severe pelvic inflammatory disease.\n* Active lower genital tract infection.\n* Pregnancy.\n* Women who do not speak fluent French or English.\n* Patients under tutelage (with or without capacity of judgement).","70 Years",{"count":82,"type":22},62,[25],"Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is a recent innovation in minimally invasive surgery which has already proven its non-inferiority to conventional abdominal laparoscopy (CAL) for hysterectomy in terms of efficiency and safety. However, the investigators note a lack of medical literature and no specific randomized controlled trial (RCT) assessing women's sexual function after vNOTES for benign adnexal surgery.\n\nThe aim of this RCT is to confirm the non-inferiority of the vNOTES approach for benign adnexal pathology compared to CAL on women's sexual function. Secondary outcomes will evaluate vNOTES's efficiency, morbidity and postoperative complications compared to CAL for benign adnexal surgery. The relationship between adnexal mass morcellation\u002Faspiration and the quality of the histological analysis on surgical specimens will also be evaluated as secondary outcome.",[86,87,88,28,89,90,62,91,92,93,94],"Gynecologic Disease","Adnexal Mass","Adnexal Cyst","Adnexal Diseases","Sexual Dysfunction","Pathology","Dyspareunia","Pelvic Pain","Complication","2025-03-24",{"date":97,"type":38},"2025-03-27",{"date":99,"type":38},"2024-01-01",{"date":101,"type":22},"2027-04-03",{"name":103,"class":45},"Jean Dubuisson",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":5},"100510952","study-of-the-prevalence-of-sexual-dysfunction-in-women-after-rectal-cancer-surgery-and-analysis-of-the-impact-of-a-sexologist-intervention-100510952","NCT05933122","Study of the Prevalence of Sexual Dysfunction in Women After Rectal Cancer Surgery and Analysis of the Impact of a Sexologist Intervention","RectSexQol","Inclusion Criteria:\n\n* Women\n* Diagnosis of stage I-III rectal adenocarcinoma or rectosigmoid junction with anastomosis less than 15 cm from the anal margin\n* Surgical management, preceded or not by Radio-chemotherapy, with restoration of continuity\n* Age : over 18\n* Proficiency in French or English\n\nExclusion Criteria:\n\n* Current pregnancy\n* Significant cognitive\u002Fpsychiatric disorders\n* Guardianship",{"count":112,"type":22},144,[25],"RectSexQoL is a study aiming at determining the prevalence of female sexual dysfunction after rectal cancer surgery. It has the goal as well to analyse the impact of an intervention given by a sexologist to such patients.",[116,117,28,118],"Rectal Tumor","Women","Life Quality",[120,121,122,123],"rectal cancer","women","sexuality","quality of life","2024-11-27",{"date":126,"type":38},"2024-12-02",{"date":128,"type":38},"2024-04-03",{"date":130,"type":22},"2027-10",{"name":132,"class":45},"University Hospital, Limoges",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":140,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":46},"100556920","danish-nurses-attitudes-towards-addressing-sexual-health-100556920","NCT06531382","Danish Nurses Attitudes Towards Addressing Sexual Health","Nurses Attitudes Towards Addressing Sexual Health - a Danish Crossectional Study","Inclusion Criteria:\n\n* Nurses working within the area of onkology or hematology in a danish hosptial or primary sector\n* nurses having daily contact with patients with a cancer diagnosis\n\nExclusion Criteria:\n\n* nurses not having daily contact with patients\n* nurses not working within hematology or oncology","ALL",{"count":142,"type":22},500,"Health professionals, within the field of cancer, attitude towards addressing sexual health with patients is unknown.\n\nThe aim is to investigate the attitudes of Danish cancer nurses towards addressing sexual health in their clinical work, as well as to assess differences in perceived competences and knowledge.\n\nMethod: The questionnaire Health professionals Attitudes towards Sexual Health-Danish version (PA-SH-D) is sent out to Danish cancer nurses via the Professional Society for Cancer Nurses. The questionnaire is sent out via a link via the RedCap database.\n\nThe questionnaire link is sent out to members of the Professional Association for Cancer Nurses under the Danish Nursing Council, and it is sent out via their membership register.",[28,145,90],"Communication","2024-07-30",{"date":148,"type":38},"2024-08-01",{"date":150,"type":38},"2024-06-01",{"date":148,"type":22},{"name":153,"class":45},"Rigshospitalet, Denmark",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":140,"minAge":161,"maxAge":80,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":46},"100486729","phase-2-lenvatinib-for-advanced-bone-and-soft-tissue-sarcoma-100486729","NCT05617859","Lenvatinib for Advanced Bone and Soft Tissue Sarcoma","A Multicenter, Open, One-arm Phase II Study of Ranvastinib Mesylate Capsules in the Treatment of Advanced Bone and Soft Tissue Sarcoma After Chemotherapy Failure","Inclusion Criteria:\n\n1. Ages 10-70, both male and female.\n2. The Eastern Collaborative Oncology Group (ECOG) physical status score was 0-1. Subjects with amputation can be relaxed up to 2 points.\n3. The expected survival time was ≥3 months.\n4. Subjects with bone and soft tissue sarcomas with distant metastases or locally advanced disease who were not considered suitable for surgical treatment by the investigator.\n5. Patients who had been treated with apatinib or anlotinib in the past, and the efficacy was evaluated as CR\\\\PR\\\\SD\\\\PD, and had no response to other systemic therapy after drug resistance, or had reprogression after more than 3 months.\n6. There were measurable lesions that met RECIST1.1 criteria.\n7. All acute toxicities from previous antitumor therapy or surgery resolved to grade 0-1 (according to NCI-CTCAE, version 4.03) or to enrollment\u002Fexclusion criteria by day 1 of the first cycle (C1D1), except for toxicities such as hair loss that the investigator considered to pose no safety risk to the subject.\n8. Adequate organ and bone marrow function is defined as follows:\n\n   Blood routine (no blood transfusion, no G-CSF, no medication correction within 14 days before screening) :\n\n   Neutrophil count (ANC)≥1,500\u002Fmm3(1.5×109\u002FL); Platelet count (PLT)≥100,000\u002Fmm3(100×109\u002FL); Hemoglobin (Hb)≥9g\u002FdL(90g\u002FL);\n\n   Blood biochemical:\n\n   Serum creatinine (Cr)≤1.5× upper limit of normal (ULN) or creatinine clearance (Cockroft-Gault formula)≥60ml\u002Fmin; Total bilirubin (TBIL)≤1.5×ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≤2.5×ULN, and subjects with liver metastases should ≤5×ULN;\n\n   Blood coagulation function:\n\n   International normalized ratio (INR)≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN;\n9. Urine routine: urinary protein \\\u003C2+; If urine protein ≥2+, 24-hour urine protein quantification must show protein ≤1g;\n10. Thyroid function: Thyroid stimulating hormone (TSH)≤ULN; FT3(T3) and FT4(T4) levels should be examined if they are abnormal, and normal FT3(T3) and FT4(T4) levels can be selected.\n11. Female subjects of reproductive age must have a negative serum pregnancy test within 7 days prior to medication and be willing to use a medically approved highly effective contraceptive (e.g., intrauterine device, birth control pill, or condom) during the study period and within 3 months after the last administration of the study drug; Male subjects with a female partner of reproductive age were required to undergo surgical sterilization or consent to use an effective method of contraception during the study period and for 3 months after the last study dose.\n12. I have AGREED and signed the informed CONSENT, and I am willing AND ABLE TO comply with the planned visit, study treatment, laboratory tests and other trial procedures.\n\nExclusion Criteria:\n\n1. C1D1 received the following treatments in the previous 4 weeks:\n\n   Radiotherapy, surgery, chemotherapy, immunotherapy for tumors. Other investigational drugs. Get live attenuated vaccine.\n2. Surgery and\u002For radiation therapy for bone and soft tissue sarcomas were planned during the study.\n3. Previous use of immunosuppressive drugs within 14 days prior to C1D1, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (i.e., no more than 10mg\u002F day of prednisolone or an equivalent physiological dose of another corticosteroid).\n4. Severe infection (such as the need for intravenous antibiotic, antifungal, or antiviral medication) within 4 weeks prior to C1D1, or unexplained fever \\>38.5°C during the screening period\u002Fbefore the first dose.\n5. Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90mmHg).\n6. Significant bleeding symptoms or clear bleeding tendency occurred within 3 months before C1D1, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, vasculitis, etc. Or arteriovenous thrombotic events occurring within 6 months before C1D1, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin or long-term antiplatelet therapy (aspirin ≥300mg\u002F day or clopidogrel ≥75mg\u002F day) may be required.\n7. Active heart disease in the 6 months prior to C1D1, including myocardial infarction and severe\u002Funstable angina pectoris. Left ventricular ejection fraction \\\u003C50% on echocardiography, poorly controlled arrhythmias (including QTcF interval \\>450ms in men and \\>470ms in women).\n8. C1D1 had been diagnosed with any other malignancy within 3 years prior to C1D1, except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix.\n9. Known allergy to the study drug or any of its excipients.\n10. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B surface antigen positive and HBVDNA≥500IU\u002Fml), and hepatitis C (hepatitis C antibody positive and HCV-RNA above the detection limit of the assay).\n11. Concomitant diseases (e.g., poorly controlled hypertension, severe diabetes,neurological or mental disorders, etc.) or any other conditions that, in the judgment of the investigator, seriously endanger the safety of the subjects, may confounding the results of the study, or interfere with the completion of the study.","10 Years",{"count":163,"type":22},60,[165],"PHASE2","A total of 60 patients with metastatic\u002Fsurgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.",[168,28],"Effectiveness","2023-08-17",{"date":171,"type":38},"2023-08-21",{"date":173,"type":38},"2023-04-30",{"date":175,"type":22},"2026-12-31",{"name":177,"class":178},"Henan Cancer Hospital","OTHER_GOV"]